What is the recommended dosing of senna (generic name) for a typical adult patient with constipation, considering factors such as age and impaired renal (kidney) or hepatic (liver) function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Senna Dosing for Adult Constipation

Start senna at 8.6-17.2 mg (one to two standard tablets of 8.6 mg each) once daily at bedtime, and titrate upward only if there is no response after several days. 1, 2

Standard Adult Dosing

  • Initial dose: 8.6-17.2 mg orally once daily at bedtime 1, 2
  • Maximum dose: 17.2 mg twice daily (34.4 mg total per day) 3
  • Most commercial senna tablets contain 8.6-9 mg of sennosides per tablet 1
  • The FDA-approved liquid formulation allows 10-15 mL once daily (maximum 15 mL twice daily) for adults 3

Critical dosing caveat: Clinical trials used 1 gram (1000 mg) daily, which is 10-12 times higher than standard commercial tablets, and 83% of trial participants reduced their dose due to side effects. 1, 2 This means the evidence base used excessive dosing, making the lower starting dose even more appropriate in real-world practice.

Titration Strategy

  • Goal of therapy: Achieve one non-forced bowel movement every 1-2 days 1, 2
  • If no response after several days at the starting dose, increase by one tablet (8.6 mg) 1
  • Monitor for abdominal cramping and diarrhea, which indicate the need for dose reduction 1, 2
  • In palliative care settings with weeks-to-days life expectancy, doses can be increased to 2-3 tablets (17.2-25.8 mg) two to three times daily 1, 2

Renal and Hepatic Impairment

  • Renal impairment: No dose adjustment needed—over 90% of sennosides and metabolites are excreted in feces, making senna safe in chronic kidney disease 1, 4
  • Hepatic impairment: No specific dose adjustment data available, but fecal excretion route suggests safety 1
  • Senna is preferred over magnesium-based laxatives in CKD patients due to the risk of hypermagnesemia with magnesium products 2, 4

Mechanism and Onset of Action

  • Sennosides are metabolized by gut bacteria to active metabolites (rheinanthrone and rhein) that stimulate prostaglandin E2 production and chloride secretion, enhancing colonic peristalsis 1, 4
  • Onset: Typically 6-12 hours when taken orally 1
  • Important interaction: Antibiotics may reduce senna efficacy by affecting colonic bacteria needed for activation 1, 2

Duration of Therapy

  • The American Gastroenterological Association conditionally recommends senna with low certainty evidence 1, 5
  • While clinical trials lasted only 4 weeks, longer-term use is probably appropriate, though data on tolerance and long-term side effects are limited 1
  • No evidence of tolerance development has been found in pediatric or adult literature 6

Common Side Effects and Management

  • Most common: Abdominal pain, cramping, and diarrhea—all dose-dependent 1
  • Side effects typically occur in the first week of treatment 1
  • Rare but notable: Perineal blistering can occur with high doses (≥60 mg/day) combined with prolonged stool-to-skin contact, particularly with nighttime accidents 6

Contraindications

  • Intestinal obstruction or ileus 1, 2
  • Severe dehydration 1, 2
  • Acute inflammatory bowel conditions 1, 2

When to Escalate Beyond Senna

If senna fails at maximum tolerated doses: 2

  • Add polyethylene glycol (PEG) 17 grams once daily as first-line combination therapy 2, 5
  • Consider bisacodyl 5-10 mg for short-term or rescue therapy 1, 5
  • Rule out fecal impaction with physical examination 1
  • Rule out mechanical obstruction with abdominal imaging if clinically indicated 1
  • Consider prescription secretagogues (linaclotide, plecanatide, prucalopride) for refractory cases 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bowel Regimen Management with MiraLAX and Senna

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Senna Use in Chronic Kidney Disease (CKD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Elobixibat Treatment for Chronic Constipation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.